All In Biotech

Free tool

FAERS Monitor: Thiola Ec

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211843 or its brand name (Thiola Ec, Tiopronin). Reports on generic versions are filed under their own applications.

Reports

900

Serious

341

38% of reports

Hospitalization

215

Death reported

53

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective286
  • fatigue49
  • pyrexia48
  • rash48
  • nausea45
  • product dose omission issue36
  • vomiting30
  • flank pain26
  • proteinuria26
  • urinary tract infection26
  • diarrhoea23
  • dyspepsia21
  • death20
  • headache20
  • pneumonia20

Reports by year received

View as table
YearReports
20042
20054
20071
20081
20091
20106
201133
201234
20134
20141
20151
20167
20171
20181
201923
202036
202164
2022134
2023132
2024147
2025181
202686

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,259 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
flank painSignal2665.044.51,572
proteinuriaSignal2632.021.9750
drug ineffectiveSignal2865.14.6993
dyspepsiaSignal215.03.363
urinary tract infectionSignal263.62.446
pyrexiaSignal483.22.573
product dose omission issueSignal362.92.142
rashSignal482.62.046
vomiting301.51.04
fatigue491.51.17
pneumonia201.40.92
nausea451.31.03
diarrhoea230.80.61
headache200.70.52
death200.50.48

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.